These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1355 related items for PubMed ID: 22263674

  • 1. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC, Davidson MH, Kelly MT, Setze CM.
    Am J Cardiovasc Drugs; 2012 Apr 01; 12(2):117-25. PubMed ID: 22263674
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH.
    Am J Cardiovasc Drugs; 2010 Apr 01; 10(3):175-86. PubMed ID: 20524719
    [Abstract] [Full Text] [Related]

  • 3. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K.
    J Clin Lipidol; 2012 Apr 01; 6(6):534-44. PubMed ID: 23312049
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.
    Am J Cardiovasc Drugs; 2010 Apr 01; 10(2):73-84. PubMed ID: 20136164
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC.
    Clin Ther; 2013 Aug 01; 35(8):1186-98. PubMed ID: 23891363
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
    Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA.
    Cardiovasc Drugs Ther; 2010 Dec 01; 24(5-6):421-8. PubMed ID: 20953684
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
    Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Atherosclerosis; 2009 May 01; 204(1):208-15. PubMed ID: 18996523
    [Abstract] [Full Text] [Related]

  • 8. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
    Ballantyne CM, Davidson MH, Setze CM, Kelly MT.
    J Clin Lipidol; 2011 May 01; 5(5):401-7. PubMed ID: 21981842
    [Abstract] [Full Text] [Related]

  • 9. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, Gogineni S, Wang P.
    Clin Ther; 2006 Jun 01; 28(6):933-42. PubMed ID: 16860175
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
    Goldberg AC, Bittner V, Pepine CJ, Kelly MT, Thakker K, Setze CM, Lele A, Sleep DJ.
    Am J Cardiol; 2011 Mar 15; 107(6):898-905. PubMed ID: 21247520
    [Abstract] [Full Text] [Related]

  • 13. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
    Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA.
    Cardiovasc Drugs Ther; 2011 Feb 15; 25(1):47-57. PubMed ID: 21174145
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 15; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 15. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
    Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC.
    Clin Drug Investig; 2010 Dec 15; 30(1):51-61. PubMed ID: 19995098
    [Abstract] [Full Text] [Related]

  • 16. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 15; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M.
    Am Heart J; 2004 Jul 15; 148(1):e4. PubMed ID: 15215813
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
    Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, Jones-Burton C.
    Am J Cardiol; 2011 Aug 15; 108(4):523-30. PubMed ID: 21596364
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
    Ballantyne CM, Jones PH, Kelly MT, Setze CM, Lele A, Thakker KM, Stolzenbach JC.
    Cardiovasc Drugs Ther; 2011 Feb 15; 25(1):59-67. PubMed ID: 21416219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.